Medical Condition News

RSS

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

7 Jun 2010

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

7 Jun 2010

Strained relationship with parents following stroke increases depression in daughters: Study

Adult daughters caring for a parent recovering from stroke are more prone to depression than sons, Marina Bastawrous today told the Canadian Stroke Congress, co-hosted by the Canadian Stroke Network, the Heart and Stroke Foundation, and the Canadian Stroke Consortium.

7 Jun 2010

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma.

7 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Economic, clinical benefits of HyperQ stress test presented at International Congress on Electrocardiology

BSP Biological Signal Processing Ltd., develops and markets innovative systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease based on its proprietary HyperQ technology. BSP recently presented the results of a study on the economic and clinical benefits of the HyperQ stress test in the diagnosis and management of coronary heart disease at the International Congress on Electrocardiology on June 4th, 2010.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

GRASP program reduces depression symptoms, boosts physical therapy results in stroke patients

You don't always need to build up a big sweat to reap the healing benefits of physical activity. Research has found that even a low-intense exercise program can reduce depression symptoms and boost physical therapy results in recovering stroke patients.

7 Jun 2010

Ipilimumab extends survival of metastatic melanoma patients: Study

A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients with metastatic melanoma in a large, international clinical trial. The study's researchers will report their findings simultaneously at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and in the New England Journal of Medicine.

7 Jun 2010

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

7 Jun 2010

MSKCC researchers study novel approach to treat metastatic melanoma

Physician-scientists at Memorial Sloan-Kettering Cancer Center are studying a novel approach to treat metastatic melanoma, known as immunotherapy, which uses the body's own immune system to attack cancer. Presented today at the American Society of Clinical Oncology annual meeting, encouraging new data shows - for the first time - a survival benefit in metastatic melanoma patients using an immunotherapy discovered and clinically investigated by researchers at Memorial Sloan-Kettering.

7 Jun 2010

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Pharmacyclics, Inc. today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL) and Waldenstroms Macroglobulinemia (WM). These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place this week in Chicago, IL.

7 Jun 2010

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia, provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

7 Jun 2010

Telemedicine holds key to rehabilitation of people with stroke: Researcher

Telemedicine holds the key to the rehabilitation of people with stroke living in northern, rural, remote Canadian communities, rehabilitation researcher Esmé French told the Canadian Stroke Congress today.

7 Jun 2010

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).

7 Jun 2010

Vitiligo is associated with variations in genes that play role in body's natural defenses: Scientists

Scientists including researchers from the University of Florida have discovered additional evidence that generalized vitiligo — a disease that typically causes patches of white skin on the face, neck and extremities that pop star Michael Jackson may have experienced — is associated with slight variations in genes that play a role in the body's natural defenses.

7 Jun 2010

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

Alcohol consumption, cigarette smoking associated with teen migraines, TTH : Study

A novel study by German researchers reported that alcohol consumption and cigarette smoking were associated with increased migraines and tension-type headaches in high school students. Coffee drinking and physical inactivity were associated specifically with migraines. Results of this study, the first to investigate modifiable risk factors for different types of headaches in a youth population, appear online early in Headache, a journal published by Wiley-Blackwell on behalf of the American Headache Society.

7 Jun 2010

Medical Condition News

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Strained relationship with parents following stroke increases depression in daughters: Study

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Economic, clinical benefits of HyperQ stress test presented at International Congress on Electrocardiology

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

GRASP program reduces depression symptoms, boosts physical therapy results in stroke patients

Ipilimumab extends survival of metastatic melanoma patients: Study

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

MSKCC researchers study novel approach to treat metastatic melanoma

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Telemedicine holds key to rehabilitation of people with stroke: Researcher

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Vitiligo is associated with variations in genes that play role in body's natural defenses: Scientists

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Alcohol consumption, cigarette smoking associated with teen migraines, TTH : Study

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News